These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19409930)

  • 1. Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes.
    Zhao C; Crews CJ; Derdeyn CA; Blackwell JL
    J Virol Methods; 2009 Sep; 160(1-2):101-10. PubMed ID: 19409930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates.
    Takahashi MN; Rolling JA; Owen KE
    Virol J; 2010 Feb; 7():39. PubMed ID: 20163742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters.
    Shoji M; Yoshizaki S; Mizuguchi H; Okuda K; Shimada M
    PLoS One; 2012; 7(1):e30302. PubMed ID: 22276174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein.
    Matthews DA; Cummings D; Evelegh C; Graham FL; Prevec L
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():345-353. PubMed ID: 10073694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
    Thomas MA; Song R; Demberg T; Vargas-Inchaustegui DA; Venzon D; Robert-Guroff M
    PLoS One; 2013; 8(10):e76344. PubMed ID: 24143187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Oster RA; Fujihashi K; Matthews QL
    Virol J; 2014 Jun; 11():112. PubMed ID: 24935650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine Design: Replication-Defective Adenovirus Vectors.
    Zhou X; Xiang Z; Ertl HCJ
    Methods Mol Biol; 2016; 1404():329-349. PubMed ID: 27076309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.
    Crosby CM; Nehete P; Sastry KJ; Barry MA
    J Virol; 2015 Jan; 89(1):669-75. PubMed ID: 25355873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
    Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
    mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity.
    Kurachi S; Tashiro K; Sakurai F; Sakurai H; Kawabata K; Yayama K; Okamoto H; Nakagawa S; Mizuguchi H
    Gene Ther; 2007 Aug; 14(15):1160-5. PubMed ID: 17508008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
    Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
    Front Immunol; 2019; 10():2941. PubMed ID: 31921191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
    Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.
    Domm W; Brooks L; Chung HL; Feng C; Bowers WJ; Watson G; McGrath JL; Dewhurst S
    Vaccine; 2011 Sep; 29(40):7080-9. PubMed ID: 21801777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy.
    Caley IJ; Betts MR; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
    Vaccine; 1999 Aug; 17(23-24):3124-35. PubMed ID: 10462249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.